AMPH Valuation

Amphastar Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

25.500

+0.84(3.406%)1D

AMPH Relative Valuation

AMPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AMPH is overvalued; if below, it's undervalued.

Historical Valuation

Amphastar Pharmaceuticals Inc (AMPH) is now in the Undervalued zone, suggesting that its current forward PE ratio of 7.75 is considered Undervalued compared with the five-year average of 14.65. The fair price of Amphastar Pharmaceuticals Inc (AMPH) is between 32.07 to 56.13 according to relative valuation methord. Compared to the current price of 25.50 USD , Amphastar Pharmaceuticals Inc is Undervalued By 20.48%.

Relative Value

Fair Zone

32.07-56.13

Current Price：25.50

20.48%

Undervalued

7.75

Trailing

Forward

6.25

EV/EBITDA

Amphastar Pharmaceuticals Inc. (AMPH) has a current EV/EBITDA of 6.25. The 5-year average EV/EBITDA is 8.70. The thresholds are as follows: Strongly Undervalued below 5.19, Undervalued between 5.19 and 6.94, Fairly Valued between 10.45 and 6.94, Overvalued between 10.45 and 12.20, and Strongly Overvalued above 12.20. The current Forward EV/EBITDA of 6.25 falls within the Undervalued range.

7.65

EV/EBIT

Amphastar Pharmaceuticals Inc. (AMPH) has a current EV/EBIT of 7.65. The 5-year average EV/EBIT is 10.77. The thresholds are as follows: Strongly Undervalued below 5.39, Undervalued between 5.39 and 8.08, Fairly Valued between 13.46 and 8.08, Overvalued between 13.46 and 16.16, and Strongly Overvalued above 16.16. The current Forward EV/EBIT of 7.65 falls within the Undervalued range.

25.50

Amphastar Pharmaceuticals Inc. (AMPH) has a current PS of 25.50. The 5-year average PS is 2.68. The thresholds are as follows: Strongly Undervalued below -0.37, Undervalued between -0.37 and 1.15, Fairly Valued between 4.20 and 1.15, Overvalued between 4.20 and 5.72, and Strongly Overvalued above 5.72. The current Forward PS of 25.50 falls within the Strongly Overvalued range.

5.74

P/OCF

Amphastar Pharmaceuticals Inc. (AMPH) has a current P/OCF of 5.74. The 5-year average P/OCF is 10.06. The thresholds are as follows: Strongly Undervalued below 5.02, Undervalued between 5.02 and 7.54, Fairly Valued between 12.58 and 7.54, Overvalued between 12.58 and 15.10, and Strongly Overvalued above 15.10. The current Forward P/OCF of 5.74 falls within the Undervalued range.

8.04

P/FCF

Amphastar Pharmaceuticals Inc. (AMPH) has a current P/FCF of 8.04. The 5-year average P/FCF is 11.84. The thresholds are as follows: Strongly Undervalued below -107.26, Undervalued between -107.26 and -47.71, Fairly Valued between 71.39 and -47.71, Overvalued between 71.39 and 130.94, and Strongly Overvalued above 130.94. The current Forward P/FCF of 8.04 falls within the Historic Trend Line -Fairly Valued range.

Amphastar Pharmaceuticals Inc (AMPH) has a current Price-to-Book (P/B) ratio of 1.57. Compared to its 3-year average P/B ratio of 3.03 , the current P/B ratio is approximately -48.33% higher. Relative to its 5-year average P/B ratio of 2.88, the current P/B ratio is about -45.58% higher. Amphastar Pharmaceuticals Inc (AMPH) has a Forward Free Cash Flow (FCF) yield of approximately 9.46%. Compared to its 3-year average FCF yield of 7.22%, the current FCF yield is approximately 30.98% lower. Relative to its 5-year average FCF yield of 6.16% , the current FCF yield is about 53.69% lower.

1.57

P/B

Median3y

3.03

Median5y

2.88

9.46

FCF Yield

Median3y

7.22

Median5y

6.16

Competitors Valuation Multiple

The average P/S ratio for AMPH's competitors is 27.70, providing a benchmark for relative valuation. Amphastar Pharmaceuticals Inc Corp (AMPH) exhibits a P/S ratio of 25.50, which is -7.94% above the industry average. Given its robust revenue growth of -4.38%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AMPH.O

Amphastar Pharmaceuticals Inc

Collegium Pharmaceutical Inc

Performance Decomposition

Market capitalization of AMPH decreased by 43.57% over the past 1 year. The primary factor behind the change was an decrease in Revenue Growth from 182.39M to 174.41M.

The secondary factor is the Margin Expansion, contributed -14.51%to the performance.

Overall, the performance of AMPH in the past 1 year is driven by Revenue Growth. Which is more sustainable.

-4.38%

182.39M → 174.41M

Revenue Growth

-14.51%

20.81 → 17.79

Margin Expansion

-24.68%

12.64 → 9.52

P/E Change

-43.57%